Cancer Risk Found in Zantac

Cancer Risk Found in Zantac

In September of 2019, the Food and Drug Administration (FDA) made an announcement that it had detected low levels of an impurity that could cause cancer in some products containing ranitidine. These products include the popular heartburn drug Zantac and its generic versions. Retailers such as CVS, Walgreens, and Walmart have pulled the products from their shelves. In October, drug makers issued a recall for prescription-strength Zantac. Over the counter Zantac products have not yet been affected by the recall. The manufacturers of some generic heartburn products have also instituted their own product recalls.

Cancer Risk in Zantac and Other Heartburn Drugs

The FDA conducted studies on the heartburn drugs and discovered a level of an impurity known as N-nitrodimethlamine or NDMA. Based on multiple laboratory tests, NDMA has been classified as a human carcinogen. This means that the substance may cause cancer in humans. In addition, Valisure, an online pharmacy, conducted its own studies of Zantac and also detected the impurity. There is evidence that the body may convert ranitidine, the active ingredient in some heartburn drugs, into NDMA. A study found that patients who took Zantac had NDMA levels that were 400 times more than what is considered acceptable by the FDA.

Contact an Experienced Product Liability Attorney

If you have concerns about your use of heartburn drugs and other medications, you should have your case evaluated by an experienced product liability attorney. Gregg Goldfarb has over 20 years of experience helping people injured by dangerous drugs. Contact us online or call us at 305-374-7000 to schedule a free consultation.

Previous Post
Three Types of Distracted Driving
Next Post
Can In-vehicle Technology Lead to Distracted Driving?
Menu